CXCL9 and colonic neoplasm: When CXCL9 and immunostimulatory factor OX40 ligand were delivered into a colon cancer mouse model via lentivirally transduced mesenchymal stem cells (MSCs), increased numbers of CD8+ T and NK cells and an improved efficacy of the anti-PD-1 treatment were observed [25].